指南与共识膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌的最佳管理:国际膀胱癌组推荐

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
指南 / 共识 · Eur Urol · 2026-02-21

国际膀胱癌组(IBCG)召集全球专家,通过文献回顾和改良Delphi投票(2024年8月,≥75%同意)制定肌层浸润性膀胱癌(MIBC)管理推荐。推荐强调全面临床分期和多学科诊疗,RC与三联治疗肿瘤学疗效相似,纯鳞癌或腺癌宜直接RC,其他组织学类型推荐顺铂为基础的新辅助治疗后RC。

要点

  • MIBC患者应接受全面临床分期和多学科团队诊疗。
  • 纯鳞状细胞癌或腺癌宜直接行根治性膀胱切除术。
  • 其他组织学类型推荐顺铂为基础的新辅助治疗后行RC。

核心结论

  • IBCG共识推荐为MIBC的最佳治疗排序策略提供实践指导。

研究设计与样本

  • IBCG召集全球膀胱癌专家组成工作组,回顾文献并起草推荐,于2024年8月现场会议采用改良Delphi流程投票,≥75%同意的推荐进一步细化后呈现。

主要发现

  • 当代回顾性比较提示根治性膀胱切除术(RC)与三联治疗具有相似的肿瘤学疗效。
  • 纯鳞状细胞癌或腺癌患者最好采用直接RC管理。
  • 其他组织学亚型推荐在RC前进行顺铂为基础的新辅助治疗。
  • RC后应采用风险分层的辅助治疗策略。
  • 目前尚无经过验证的预测性生物标志物可在临床试验外指导MIBC临床决策。

关键数值与推荐

  • 推荐条款经改良Delphi投票,会议中≥75%同意者被进一步细化并呈现。
  • 围手术期治疗试验推荐使用时间-事件终点,膀胱保留试验推荐膀胱完整无事件生存,并强调纳入患者报告的生活质量终点。

临床怎么用

  • 临床实践中应对MIBC进行彻底临床分期和多学科诊疗。
  • 根据组织学类型选择治疗顺序:纯鳞癌或腺癌直接RC,其他亚型行顺铂为基础新辅助治疗后RC。
  • RC后根据风险分层选择辅助治疗。
  • 临床试验设计时围手术期治疗采用时间-事件终点,膀胱保留试验采用膀胱完整无事件生存并纳入生活质量终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The management of muscle-invasive bladder cancer (MIBC) is evolving rapidly with the emergence of new perioperative treatments and approaches for bladder preservation. We provide guidance on clinical staging and optimal therapeutic sequencing for patients with MIBC in clinical practice and within the context of clinical trial design. METHODS: The International Bladder Cancer Group (IBCG) convened global experts in bladder cancer to develop recommendations for the management of MIBC and to guide clinical trial design. Working groups reviewed the literature and developed draft recommendations. This was followed by voting by the IBCG members during a live meeting in August 2024 using a modified Delphi process. Recommendations achieving ≥75% agreement during the meeting were further refined and presented. KEY FINDINGS AND LIMITATIONS: The IBCG recommends thorough clinical staging and multidisciplinary care for patients with MIBC. Contemporary retrospective comparisons suggest that radical cystectomy (RC) and trimodal therapy have similar oncologic efficacy. Patients with pure squamous-cell carcinoma or adenocarcinoma are best managed with upfront RC, while cisplatin-based neoadjuvant therapy before RC is recommended for other histologic subtypes. Risk-stratified adjuvant therapy approaches should be used after RC. There are no currently validated predictive biomarkers to guide clinical decision-making in MIBC outside the context of a clinical trial. The IBCG recommends the use of time-to-event endpoints for perioperative therapy trials, and bladder-intact event-free survival for bladder preservation trials, with an emphasis on incorporating patient-reported quality-of-life endpoints. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on optimal treatment sequencing strategies in the management of MIBC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gupta S, Li R, Hensley PJ, et al. Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2026. PMID: 41724648. doi:10.1016/j.eururo.2026.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。